Acute Promyelocytic LeukemiaSymptoms, Doctors, Treatments, Advances & More
Learn About Acute Promyelocytic Leukemia
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Dana-Farber Cancer Institute, Adult Leukemia Program
Richard Stone is a Hematologist Oncology specialist and a Hematologist practicing medicine in Boston, Massachusetts. Dr. Stone is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Stone is board certified in Hematology, Internal Medicine, and Medical Oncology.
Jessica Altman is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. She has been practicing medicine for over 25 years. Dr. Altman is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Altman is board certified in American Board Of Internal Medicine - Hematology (Certified).
Office
Hagop Kantarjian is an Oncologist practicing medicine in Houston, Texas. Dr. Kantarjian is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. He is also highly rated in 47 other conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Summary: This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Background: \- Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.